Teva's Viagra copy to stay on Russian market

Teva Pharmaceutical Industries may have failed at challenging Pfizer's Viagra patent in the U.S., but its efforts in Russia have been more successful. A quick patent fight has ended in settlement, giving Teva the chance to keep selling its version of the erectile dysfunction remedy.

The Israeli generics maker started selling its Viagra copycat in Russia in August, under the brand name Dynamico. Pfizer ($PFE) sued, of course, claiming in a Moscow court that Teva had violated its patent rights. The U.S.-based company had sold $117 million worth of Viagra in Russia in 2010, making it the third-biggest-selling drug in the country.

But as PharmaLetter now reports, that dispute appears to be wrapped up. Teva will keep selling Dynamico in the Russian market. Just how Pfizer and Teva settled their patent fight isn't clear, nor are the terms under which Teva will market the drug. The research firm Pharmexpert told Reuters earlier this year that for the first 8 months of 2011, Viagra sales in Russia were up 14% by $86.7 million.

In August, Pfizer won a U.S. patent infringement case against Teva, in a ruling that will prohibit the generics maker from selling its Viagra copy till 2019. Teva has appealed the decision, but since then, Pfizer has also won more than $370,000 in attorneys fees in the same case.

- read the PharmaLetter piece

- get more from Reuters

Related Articles:
Teva Pharmaceutical Industries - 10 Largest U.S. Patent Losses
Pfizer wins Viagra patent case against Teva
Pfizer just might postpone Viagra's patent cliff

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.